Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of BioChaperone Combo vs Humalog Mix25 and Humalog+Lantus
NCT05373186Phase 1Completed
- Sponsor
- Adocia
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BioChaperone glargine lispro in diabetes mellitus (DM) (3 arms), sponsored by Adocia. Primary endpoint: Area Under the Curve of Glucose Infusion Rate from 0 to 2 hours. Started May 2022; status: completed.
02
Drugs
BioChaperone glargine lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05373186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373186.